Chinese antibody maker, famed for Ebola cocktail, notches $160M as it focuses on cancer, autoimmune drugs
Big name investors have come together to bring Chinese biotech Mabworks’ Series C haul to $160 million, boosting a biologics pipeline that spans a number …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
